Intravenous immunoglobulin–related hemolysis in patients treated for Kawasaki disease

Transfusion

Volumn 55, Issue S2, 2015, Pages S90-S94

  Luban, Naomi L C ^a   Wong, Edward C C ^a   Lobo, Rodolfo Henrich ^a   Pary, Philippe ^a   Duke, Sarah ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR;

ADOLESCENT; ANEMIA; CASE REPORT; CHEMICALLY INDUCED; CHILD; DRUG EFFECTS; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOLYSIS; HUMAN; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ADOLESCENT; ANEMIA; CHILD; CHILD, PRESCHOOL; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOLYSIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; RETROSPECTIVE STUDIES;

EID: 84942419559     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/TRF.13089     Document Type: Article

References (30)

1. Burns JC, Glodé MP. Kawasaki syndrome. Lancet 2004;364: 533-44.
2. Onouchi Y. Molecular genetics of Kawasaki disease. Pediatr Res 2009;65(5 Pt 2):46R-54R.
3. Eleftheriou D, Levin M, Shingadia D, et al. Management of Kawasaki disease. Arch Dis Child 2014;99:74-83.
4. Kawasaki T, Kosaki F, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatric 1974;54:271-6.
5. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33.
6. Bayers S, Shulman ST, Paller AS. Kawasaki disease: part II. Complications and treatment. J Am Acad Dermatol 2013;69: 513.e1-8.
7. Bunin NJ, Carey JL, Sullivan DB. Autoimmune hemolytic anemia in association with Kawasaki disease. Am J Pediatr Hematol Oncol 1986;8:351-3.
8. Gupta GJ, Noel M, Schaefer D, et al. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immun 2001;21:193-9.
9. Ohashi R, Fukazawa R, Watanabe M, et al. Etanercept suppresses arteritis in murine model of Kawasaki disease: a comparative study involving different biological agents. Int J Vasc Med 2013;2013:543141.
10. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117(4 suppl):S525-53.
11. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014;9:CD002063.
12. Wolf VL, Lupo PJ, Lotze TE. Pediatric acute transverse myelitis overview and differential diagnosis. J Child Neurol 2012; 27:1426-36.
13. Louis D, More K, Oberoi S, et al. Intravenous immunoglobulin in isoimmune haemolytic disease of the newborn: an updated systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2014;99:F325-31.
14. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003;17:241-51.
15. Lau AC, Duong TT, Ito S, et al. Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. Arthritis Rheum 2009;60:2131-41.
16. Barron KS, Murphy DJ, Silverman E, et al. Treatment of Kawasaki syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. J Pediatr 1990;117:638-44.
17. Berard R, Whittemore B, Scuccimarri R. Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases. Pediatr Rheumatol Online J 2012;10:10.
18. Brox AG, Cournoyer D, Sternbach M, et al. Hemolytic anemia following intravenous gamma globulin administration. Am J Med 1987;82(3 Spec No):633-5.
19. Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008; 48:1598-601.
20. Kim HC, Park CL, Cowan JH 3rd, et al. Massive intravascular hemolysis associated with intravenous immunoglobulin in bone marrow transplant recipients. Am J Pediatr Hematol Oncol 1988;10:69-74.
21. Comenzo RL, Malachowski ME, Meissner HC, et al. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr 1992;120:926-8.
22. Nakagawa M, Watanabe N, Okuno M, et al. Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease. Am J Hematol 2000;63:160-1.
23. Gordon DJ, Sloan SR, de Jong JL. A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin. Am J Hematol 2009;84:771-2.
24. Hillyer CD, Schwenn MR, Fulton DR, et al. Autoimmune hemolytic anemia in Kawasaki disease: a case report. Transfusion 1990;30:738-40.
25. Pickering LK, Baker CJ, et al., editors. Red Book. 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove (IL): American Academy of Pediatrics; 2012.
26. Ni FF, Li CR, Li Q, et al. Regulatory T cell microRNA expression changes in children with acute Kawasaki disease. Clin Exp Immunol 2014;178:784-93.
27. Olivito B, Taddio A, Simonini G, et al. Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin Exp Rheumatol 2010;28:93-7.
28. Oates-Whitehead RM, Baumer JH, Haines K, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2003;(4):CD004000.
29. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888-9.
30. Berg R, Shebe A, Schreiber G, et al. Hemolytic events associated with intravenous immune globin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012. Transfusion 2015;55 (Suppl 2):S36-S46.